Drug Profile

LS 007 - Le Sun Pharmaceuticals

Alternative Names: LS-007

Latest Information Update: 03 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Le Sun Pharmaceuticals
Developer Cancer Research UK
Class Antineoplastics; Small molecules
Mechanism of Action Cyclin-dependent kinase 9 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Acute myeloid leukaemia

Most Recent Events

20 Oct 2023 Le Sun Pharmaceuticals has patent protection for LS 007 worldwide
20 Oct 2023 Phase-I clinical trials in Acute myeloid leukaemia in China (PO) before October 2023 (Cancer Research UK pipeline, October 2023)
29 Mar 2019 Le Sun Pharmaceuticals announces approval of IND application for LS 007 for the treatment of Acute myeloid leukaemia

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com